If you have been reading about reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-11. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
In 2011, Domino's launched a billboard advertising in New York's Times Square which displayed real time comments from customers, including good, neutral and bad comments. In 2015, Domino's unveiled a "pizza car" that can carry 80 pizzas, sides, two-liter bottles of soda, and dipping sauces. It also has a 140 °F (60 °C) oven on board and is more fuel efficient than a standard delivery car. Officially named the Domino's DXP, the car is a Chevrolet Spark customized by Roush Performance. Once each car reaches 100,000 miles, it will be retired and returned to Roush, where it will be returned to stock form. In 2016, Domino's cooperated with Starship Technologies and applied self-driving robots to deliver pizzas in specific German and Dutch cities. In 2016, Domino's in New Zealand delivered the world's first pizza delivery by unmanned aerial vehicle using the DRU Drone by Flirety. In February 2017, Domino's launched a wedding registry with gifts delivered in the form of Domino's eGift cards. Domino's also worked with Gugu Guru to create a pizza-themed baby registry. Customers have the option of signing up for Domino's pizza package to be served for the event. In June 2019, Domino's announced a partnership with robotics company Nuro. The service is slated to launch in Houston, Texas, with Nuro's custom, self-driving vehicle, R2. In December 2021, the company began offering "surprise frees," or complimentary items as part of a delivery process, of up to $50 million. The move was made to distinguish the company from delivery apps that charged fees.
== Channel distribution == The majority of P-type calcium channels are located in the nervous system and heart. Antibody labeling is the primary method used to identify channel location. Areas of high expression in mammalian systems include:
== Education == Foyer attended Portsmouth Polytechnic (now the University of Portsmouth) from 1971–74, achieving a BSc with Class II, Division I Honours in Biology (CNAA). From 1974–77 she attended the Department of Biochemistry, King's College London, where she completed her PhD. During this time Foyer also attended a course on immunology at Chelsea College, London. In 1998 Foyer was elected a Fellow of the Institute of Biology.
== References == Siegel, David P.; Cherezov, V.; Greathouse, D. V.; Koeppe, R. E.; Antoinette Killian, J.; Caffrey, M. (January 2006). "Transmembrane Peptides Stabilize Inverted Cubic Phases in a Biphasic Length-Dependent Manner: Implications for Protein-Induced Membrane Fusion". Biophysical Journal. 90 (1). Biophysical Society: 200–211. Bibcode:2006BpJ....90..200S. doi:10.1529/biophysj.105.070466. PMC 1367019. PMID 16214859. Weiss, Thomas M.; Van der Wel, Patrick C.A.; Antoinette Killian, J.; Koeppe, II, Roger E.; Huang, Huey W. (January 2003). "Hydrophobic Mismatch between Helices and Lipid Bilayers". Biophysical Journal. 84 (1). Biophysical Society: 379–385. Bibcode:2003BpJ....84..379W. doi:10.1016/S0006-3495(03)74858-9. PMC 1302619. PMID 12524291. Kim, Taehoon; Im, Wonpil (July 2010). "Revisiting Hydrophobic Mismatch with Free Energy Simulation Studies of Transmembrane Helix Tilt and Rotation". Biophysical Journal. 99 (6). Biophysical Society: 175–183. Bibcode:2010BpJ....99..175K. doi:10.1016/j.bpj.2010.04.015. PMC 2895360. PMID 20655845.
Sources: en.wikipedia.org
==== Vaso-occlusive crisis ==== Also termed "sickle cell crisis" or "sickling crisis", the vaso-occlusive crisis (VOC) manifests principally as extreme pain, most often affecting the chest, back, legs, and/or arms. The underlying cause is sickle-shaped red blood cells that obstruct capillaries and restrict blood flow to an organ, resulting in ischaemia, pain, necrosis, and often organ damage. The frequency, severity, and duration of these crises vary considerably. Milder crises can be managed with nonsteroidal anti-inflammatory drugs. For more severe crises, patients may require inpatient management for intravenous opioids. Vaso-occlusive crisis involving organs such as the lungs or the penis are considered an emergency and treated with red blood cell transfusions. A VOC can be triggered by anything which causes blood vessels to constrict; this includes physical or mental stress, cold, and dehydration. "After Haemoglobin S (HbS) deoxygenates in the capillaries, it takes some time (seconds) for HbS polymerization and the subsequent flexible-to-rigid transformation. If the transit time of RBC through the microvasculature is longer than the polymerization time, sickled RBC will lodge in the microvasculature."
Alexander (1940), political activist, writer, and professor at Rutgers University John Hine Mundy (1940), British-American medievalist, professor at Columbia University, former president of the Medieval Academy of America Donald Barr (1941), educator and author; former headmaster of Dalton School; initiated the Columbia University Science Honors Program Ted de Bary (1941), East Asian studies expert and provost of Columbia University Leon Henkin (1941), mathematician and logician at University of California, Berkeley Donald Keene (1942), scholar of Japanese culture Robert Lekachman (1942), economist Philip Yampolsky (1942), scholar of Zen Buddhism Francesco Cordasco (1943), professor of education at Montclair State University Bernard Russell Gelbaum (1943), professor of mathematics at University of California, Irvine Martin S. James (1943), art historian, translator of Piet Mondrian Martin J. Klein (1943), historian of science and recipient of the Abraham Pais Prize for History of Physics Bernard Weisberger (1943), historian of the Reconstruction Era Alan Hoffman (1944), mathematician known for constructing the Hoffman–Singleton graph Bruce Mazlish (1944), historian and professor at Massachusetts Institute of Technology, son-in-law of David Rockefeller Richard Popkin (1944), philosopher Jack Greenberg (1945), counsel for the NAACP, in which capacity he argued Brown v. Board of Education; former professor at Columbia Law School and dean of Columbia College Murray Rothbard (1945), leading exponent of the Austrian School of economics Gilbert Y.
Dog saliva has been said by many cultures to have curative powers in people. "Langue de chien, langue de médecin" is a French saying meaning "A dog's tongue is a doctor's tongue", and a Latin quote that "Lingua canis dum lingit vulnus curat" or "A dog's saliva can heal your wound" appears in a thirteenth-century manuscript. In Ancient Greece, dogs at the shrine of Aesculapius were trained to lick patients, and snake saliva was also applied to wounds. Saint Roch in the Middle Ages was said to have been cured of a plague of sores by licking from his dog. The Assyrian Queen Semiramis is supposed to have attempted to resurrect the slain Armenian king Ara the Beautiful by having the dog god Aralez lick his wounds. In the Scottish Highlands in the nineteenth century, dog saliva was believed to be effective for treating wounds and sores. In the Gospel of Luke (16:19-31), Lazarus the Beggar's sores are licked by dogs, although no curative effects are reported by the Evangelist.
The post–Cold War era is a period of history that has been ongoing since the dissolution of the Soviet Union, which began in 1988 and marked the end of the Cold War by 1991, thereby leaving the United States as the world's sole superpower. At the same time, Europe experienced the collapse of communism alongside the fall of the "Iron Curtain" between the American-aligned Western Bloc and the Soviet-aligned Eastern Bloc, which gradually embraced market economies. The establishment of the European Union (EU) in 1993 effectively reversed the continent's Cold War divide by absorbing most of Eastern Europe and integrating it with Western Europe over the course of three enlargements. Relative to the Cold War, the period is characterized by stabilization and disarmament. Both Russia (the Soviet Union's legal successor state) and the United States significantly reduced their nuclear weapons stockpiles, and most Eastern Bloc countries became democratic and were integrated into the global economy. In the first two decades of the post–Cold War era, the North Atlantic Treaty Organization (NATO) underwent three enlargements and France re-integrated into the NATO command, while Russia founded the Collective Security Treaty Organization (CSTO) to replace the Warsaw Pact. More recently, China has become a rising power and has likewise consolidated a greater role on the international stage while building a strategic partnership with Russia, with both countries working in BRICS and the Shanghai Cooperation Organization.
The United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 is one of three major drug control treaties currently in force. It provides additional legal mechanisms for enforcing the 1961 Single Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances. The Convention entered into force on November 11, 1990. As of June 2020, there are 191 Parties to the convention. These include 186 out of 193 United Nations member states (not Equatorial Guinea, Kiribati, Papua New Guinea, Solomon Islands, Somalia, South Sudan, or Tuvalu) and the Holy See, the European Union, the Cook Islands, Niue, and the State of Palestine.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.